A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand | Zendy

Darshan Mehta | Zendy; Abiola Oladapo | Zendy; J. Epstein | Zendy; Aaron Novack | Zendy; Ellis J. Neufeld | Zendy; Joel W. Hay | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand

Author(s) -

Darshan Mehta,

Abiola Oladapo,

J. Epstein,

Aaron Novack,

Ellis J. Neufeld,

Joel W. Hay

Publication year - 2016

Publication title -

journal of managed care and specialty pharmacy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.126

H-Index - 63

eISSN - 2376-1032

pISSN - 2376-0540

DOI - 10.18553/jmcp.2016.22.2.149

Subject(s) - medicine , recombinant factor viia , bleed , dosing , clotting factor , clinical trial , hemostasis , randomized controlled trial , intensive care medicine , surgery

Hemophilia patients use factor-clotting concentrates (factor VIII for hemophilia A and factor IX for hemophilia B) for improved blood clotting. These products are used to prevent or stop bleeding episodes. However, some hemophilia patients develop inhibitors (i.e., the patient's immune system develops antibodies against these factor concentrates). Hence, these patients do not respond well to the factor concentrates. A majority of hemophilia patients with inhibitors are managed on-demand with the following bypassing agents: recombinant factor VIIa (rFVIIa) and activated prothrombin complex concentrate (aPCC). The recently published U.S. registries Dosing Observational Study in Hemophilia (DOSE) and Hemostasis and Thrombosis Research Society (HTRS) reported higher rFVIIa on-demand use for bleed management than previously described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research